SuperworthBeam Therapeutics market cap BEAM
Share price times shares outstanding: what the whole company sells for, since 2020.
- Today, Oct 23, 2026
- $2.5B
- Highest close in our data
- $8.1B
- Jul 2021
Beam Therapeutics is worth $2.5B at the close on Oct 23, 2026, at $24.05 a share.
That is down 12% over the last year and down 58% over five years.
Its highest close in our data was $8.1B in Jul 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $2.5B | $2.3B | $3.6B | −13% |
| 2025 | $2.8B | $1.3B | $2.8B | +29% |
| 2024 | $2.2B | $1.7B | $3.3B | −1% |
| 2023 | $2.2B | $1.4B | $3.4B | −20% |
| 2022 | $2.8B | $2.3B | $5.1B | −49% |
| 2021 | $5.4B | $4.2B | $8.1B | +15% |
| 2020 | $4.7B | $995.7M | $5.1B | n/a |
Against its peers
Companies in Biotechnology nearest Beam Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| BEAMBeam Therapeutics | $2.5B |
| ADMAAdma Biologics | $2.4B |
| VCELVericel | $2.2B |
| MGTXMeiraGTx | $884.6M |
| KRYSKrystal Biotech | $9.2B |
| RGENRepligen | $10B |
| TECHBIO-TECHNE | $11.4B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| INCYIncyte | $23.5B |
| Peer median | $10.7B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Beam Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.